Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2012 1
2014 1
2016 2
2017 2
2018 1
2019 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Prognostic significance of MEOX2 in gliomas.
Tachon G, Masliantsev K, Rivet P, Petropoulos C, Godet J, Milin S, Wager M, Guichet PO, Karayan-Tapon L. Tachon G, et al. Among authors: rivet p. Mod Pathol. 2019 Jun;32(6):774-786. doi: 10.1038/s41379-018-0192-6. Epub 2019 Jan 18. Mod Pathol. 2019. PMID: 30659268 Free article.
Crizotinib targets in glioblastoma stem cells.
Junca A, Villalva C, Tachon G, Rivet P, Cortes U, Guilloteau K, Balbous A, Godet J, Wager M, Karayan-Tapon L. Junca A, et al. Among authors: rivet p. Cancer Med. 2017 Nov;6(11):2625-2634. doi: 10.1002/cam4.1167. Epub 2017 Sep 27. Cancer Med. 2017. PMID: 28960893 Free PMC article.
A radiosensitizing effect of RAD51 inhibition in glioblastoma stem-like cells.
Balbous A, Cortes U, Guilloteau K, Rivet P, Pinel B, Duchesne M, Godet J, Boissonnade O, Wager M, Bensadoun RJ, Chomel JC, Karayan-Tapon L. Balbous A, et al. Among authors: rivet p. BMC Cancer. 2016 Aug 5;16:604. doi: 10.1186/s12885-016-2647-9. BMC Cancer. 2016. PMID: 27495836 Free PMC article.
Clinical validation of the CE-IVD marked Therascreen MGMT kit in a cohort of glioblastoma patients.
Quillien V, Lavenu A, Ducray F, Meyronet D, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D. Quillien V, et al. Among authors: rivet p. Cancer Biomark. 2017 Dec 6;20(4):435-441. doi: 10.3233/CBM-170191. Cancer Biomark. 2017. PMID: 28800313 Free article.
Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial.
Quillien V, Lavenu A, Ducray F, Joly MO, Chinot O, Fina F, Sanson M, Carpentier C, Karayan-Tapon L, Rivet P, Entz-Werle N, Legrain M, Zalcman EL, Levallet G, Escande F, Ramirez C, Chiforeanu D, Vauleon E, Figarella-Branger D. Quillien V, et al. Among authors: rivet p. Oncotarget. 2016 Sep 20;7(38):61916-61929. doi: 10.18632/oncotarget.11322. Oncotarget. 2016. PMID: 27542245 Free PMC article.
O6-Methylguanine-methyltransferase (MGMT) promoter methylation status in glioma stem-like cells is correlated to temozolomide sensitivity under differentiation-promoting conditions.
Villalva C, Cortes U, Wager M, Tourani JM, Rivet P, Marquant C, Martin S, Turhan AG, Karayan-Tapon L. Villalva C, et al. Among authors: rivet p. Int J Mol Sci. 2012;13(6):6983-6994. doi: 10.3390/ijms13066983. Epub 2012 Jun 7. Int J Mol Sci. 2012. PMID: 22837675 Free PMC article.
11 results